%0 Journal Article
%T Broad Spectrum Antiangiogenic Treatment for Ocular Neovascular Diseases
%A Ofra Benny
%A Kei Nakai
%A Takeru Yoshimura
%A Lauren Bazinet
%A James D. Akula
%A Shintaro Nakao
%A Ali Hafezi-Moghadam
%A Dipak Panigrahy
%A Pouya Pakneshan
%A Robert J. D'Amato
%J PLOS ONE
%D 2012
%I Public Library of Science (PLoS)
%R 10.1371/journal.pone.0012515
%X Pathological neovascularization is a hallmark of late stage neovascular (wet) age-related macular degeneration (AMD) and the leading cause of blindness in people over the age of 50 in the western world. The treatments focus on suppression of choroidal neovascularization (CNV), while current approved therapies are limited to inhibiting vascular endothelial growth factor (VEGF) exclusively. However, this treatment does not address the underlying cause of AMD, and the loss of VEGF's neuroprotective can be a potential side effect. Therapy which targets the key processes in AMD, the pathological neovascularization, vessel leakage and inflammation could bring a major shift in the approach to disease treatment and prevention. In this study we have demonstrated the efficacy of such broad spectrum antiangiogenic therapy on mouse model of AMD.
%U http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0012515